A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients With Moderate to Severe Plaque Psoriasis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs IMO 8400 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 24 Mar 2015 Results presented at the 73rd Annual Meeting of the American Academy of Dermatology.
    • 08 Dec 2014 According to an Idera Pharmaceuticals media release, clinical safety results of this and other trial (see profile 224829) were presented at 56th Annual Meeting of the American Society of Hematology .
    • 18 Jun 2014 New source identified and integrated (European Clinical Trials Database: EudraCT2013-000164-28)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top